EP1711130A1 - Bileaflet prosthetic valve and method of manufacture - Google Patents

Bileaflet prosthetic valve and method of manufacture

Info

Publication number
EP1711130A1
EP1711130A1 EP05705043A EP05705043A EP1711130A1 EP 1711130 A1 EP1711130 A1 EP 1711130A1 EP 05705043 A EP05705043 A EP 05705043A EP 05705043 A EP05705043 A EP 05705043A EP 1711130 A1 EP1711130 A1 EP 1711130A1
Authority
EP
European Patent Office
Prior art keywords
leaflet
prosthetic valve
valve
leaflets
prosthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05705043A
Other languages
German (de)
French (fr)
Inventor
Carol E. Eberhardt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc filed Critical Medtronic Inc
Publication of EP1711130A1 publication Critical patent/EP1711130A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2415Manufacturing methods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/0075Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable

Definitions

  • the present invention relates to an implantable prosthetic valve. More particularly, the present invention relates to a bileaflet implantable prosthetic valve with redundant coaptation to be implanted during heart valve replacement surgery.
  • Heart valve replacement surgery There are four valves of the heart, the mitral valve, the aortic valve, the tricuspid valve, and the pulmonary valve.
  • each valve forms or defines a valve annulus and valve leaflets.
  • the mitral valve differs significantly in anatomy from the other valves, in particular, the aortic valve.
  • the annulus of the mitral valve is somewhat "D" shaped or elongated whereas the annulus of the aortic valve is more nearly circular.
  • the mitral valve includes two leaflets that are oval or "D" shaped, in contrast to the aortic valve, which includes three leaflets that are more nearly circular. Mitral valves are also subject to higher pressure and longer closure periods than are aortic valves. To accommodate such conditions, native mitral valves incorporate redundant coaptation.
  • redundant coaptation is used to refer to closure of the valve at more than one line of interaction between the leaflets.
  • the native mitral valve leaflets interact during closure tightly mating or coapting along a first line.
  • the native mitral valve leaflets also interact or coapt at multiple points between the first line and the free edges of the leaflets (i.e., the edges of the leaflets not attached to the remaining valve).
  • the native mitral valve leaflets close to interact or coapt with one another such that the free edges are gathered or puckered rather than held substantially taut.
  • the repetitious or redundant coaptation bolsters the integrity of the valve to better maintain closure during relatively long periods and to better withstand the high closure pressures.
  • Any heart valve can be subjected to or incur damage that requires the valve to be repaired or replaced.
  • a majority of patients with heart valve disease undergo heart valve replacement surgery rather than heart valve repair.
  • Various types and configurations of prosthetic heart valves are used to replace diseased, human heart valves. In general terms, the prosthetic heart valve design attempts to replicate the function of the valve being replaced and thus will include valve or leaflet-like structures.
  • prosthetic heart valves are generally classified as either forming relatively rigid leaflets or forming relatively flexible leaflets.
  • the category including prosthetic heart valves which form relatively flexible leaflets includes bioprosthetic heart valves having leaflets made of a biological material as well as prosthetic heart valves having leaflets made of synthetic (e.g., polymeric) material.
  • Flexible leaflet prosthetic heart valves are generally categorized as having a frame or a stent or as having no stent.
  • the porcine aortic valve is typically used to make both the aortic and mitral prosthetic valves. More commonly, a single type of prosthetic porcine valve is manufactured and used for replacement of both the aortic and mitral valves.
  • the aortic porcine valve is circular, similar to the native human aortic valve. However, as previously described, the native human mitral valve is more oval or elongated than circular. Therefore, during implantation, the typical mitral valve prosthetic made from a porcine aortic valve must be forced to conform to the non-circular annulus of the native mitral valve.
  • a porcine aortic valve and the resulting prosthetic valves each have three leaflets while a native mitral valve has only two leaflets.
  • the conventional tri-leaflet prosthetic valves do not incorporate redundant coaptation while closed and, therefore, such prosthetic valves are not specifically designed to withstand the higher pressures and longer closure periods experienced by the mitral valve.
  • the anatomy of the prosthetic valves typically used to replace a mitral valve do not sufficiently replicate the native mitral valve anatomy.
  • flexible leaflet, prosthetic valves have been developed incorporating the bileaflet anatomy of the native mitral valve.
  • Figures 1 A and IB illustrate a prior art bileaflet, prosthetic valve generally at 10.
  • the conventional prosthetic valve 10 includes a stent 12 (generally indicated), a first leaflet 14, and a second leaflet 16.
  • the stent 12 defines an annular ring 18, a first strut 20, and a second strut 22.
  • the first strut 20 is coupled with and extends from the annular ring 18 to form a rounded tip 24.
  • the second strut 22 is diametrically opposed to the first strut 20 and is coupled with and extends from the annular ring 18 to form a rounded tip 26.
  • the first leaflet 14 is coupled with the stent 12 by suturing the first leaflet 14 to the annular ring 18 and the first and second struts 20 and 22.
  • the first leaflet 14 extends between the struts 20 and 22 to define a free edge 30 opposite the annular ring 18.
  • the second leaflet 16 is coupled with the stent 12 by suturing the second leaflet 16 to the annular ring 18 and the struts 20 and 22. Therefore, the second leaflet 16 extends between the struts 20 and 22 opposite the first leaflet 14 to define a free edge 32 opposite the annular ring 18.
  • the prosthetic valve 10 closes such that the free edge 30 and the free edge 32 coapt or fit together to tightly close the prosthetic valve 10. In particular, the free edges 30 and 32 directly abut one another in the closed position.
  • the intersection between the free edges 30 and 32 defines a catenary 34 between the first tip 24 of the first strut 20 and the second tip 26 of the second strut 22.
  • the catenary 34 is more precisely an imaginary curve that extends between and, in effect, hangs from, the first tip 24 and the second tip 26.
  • the catenary 34 represents the first and only line of interaction between the first and second leaflets 14 and 16 during closure. When in the closed position, the first leaflet 14 and the second leaflet 16 are each maintained in a relatively taut manner.
  • each of the free edges 30 and 32 has a length equal to the length of the catenary 34 (FIG. 1 A).
  • the prosthetic mitral valve 10 upon opening, the prosthetic mitral valve 10, more particularly the free edges 30 and 32, form an opening 36 having a perimeter substantially equal to twice the length of the catenary 34. As such, the length of the catenary 34 limits the size of the opening 36, which may impede blood flow through the valve prosthetic 10.
  • Conventional flexible leaflet, prosthetic valves having no stent typically are tri- leaflet valves that tightly coapt such that the free edges of each leaflet abut one another upon closure of the stentless valve. Often, an entirety (i.e., the valve annulus and leaflets) of a porcine aortic valve is harvested, treated, and used as the replacement valve in heat valve replacement surgery.
  • conventional stentless valves are not constructed or modified to withstand relatively high pressures and prolonged closing intervals.
  • the leaflets of a typical prosthetic valves upon closure, are maintained in a relatively taut manner.
  • the taut leaflets are in contrast to the puckered leaflets of the native mitral valve, which provide for redundant coaptation, a stronger valve closure, and a larger valve opening.
  • a prosthetic valve including a body, a first leaflet, and a second leaflet.
  • the first leaflet extends across and is coupled to the body.
  • the first leaflet is cut from a first porcine aortic valve and defines a first inner surface.
  • the second leaflet extends across and is coupled to the body opposite the first leaflet.
  • the second leaflet is cut from a second porcine aortic valve and defines a second inner surface.
  • Another aspect of the present invention relates to a prosthetic valve including a body, a first leaflet, and a second leaflet.
  • the first leaflet extends across and is sutured to the body.
  • the first leaflet has an elongated shape.
  • the second leaflet extends across and is sutured to the body opposite the first leaflet.
  • the second leaflet has an elongated shape.
  • Another aspect of the present invention relates to a prosthetic valve including a body, a first leaflet, and a second leaflet.
  • the first leaflet extends across and is sutured to the body.
  • the first leaflet is cut from a first porcine aortic valve, defines a first inner surface, and has an elongated shape.
  • the second leaflet extends across and is sutured to the body opposite the first leaflet.
  • the second leaflet is cut from a second porcine aortic valve, defines a second inner surface, and has an elongated shape.
  • Yet another aspect of the present invention relates to a method of manufacturing a prosthetic mitral valve.
  • the method includes providing a body, cutting a first leaflet defining a first inner surface from a first porcine aortic valve, coupling the first leaflet to the body, cutting a second leaflet defining a second inner surface from a second porcine aortic valve, and coupling the second leaflet to the body opposite the first leaflet.
  • Figure 1 A is a perspective view of a prior art prosthetic valve in a closed position
  • Figure IB is a perspective view of the prior art prosthetic valve illustrated in Figure 1 A in an open position
  • Figure 2 is a perspective view of one embodiment of a bileaflet prosthetic valve in a closed position in accordance with the present invention
  • Figure 3 is a perspective view of the bileaflet prosthetic valve illustrated in Figure 2 in an opened position
  • Figure 4 is a perspective view of one embodiment of a stent and a cloth covering of the bileaflet prosthetic valve illustrated in Figure 2
  • Figure 5 A is a schematic view of one embodiment of a left cusp of a porcine aortic valve for use in the bileaflet prosthetic valve illustrated in Figure 2
  • Figure 5B is a schematic view of one embodiment of another left cusp of a porcine aortic valve for use in the bileaflet prosthetic valve illustrated in Figure 2
  • Figure 6 is a perspective view of one embodiment
  • the prosthetic valve 40 includes a body 42, a first leaflet 44, and a second leaflet 46.
  • the body 42 serves as the support structure to which the first leaflet 44 and the second leaflet 46 are opposingly attached.
  • the leaflets 44 and 46 are attached such that in a closed position, as illustrated in Figure 2, the first leaflet 44 interacts with the second leaflet 46 to close the prosthetic valve 40. More precisely, the first leaflet 44 and the second leaflet 46 redundantly coapt to close and to prevent blood flow through the prosthetic valve 40prosthetic valve 40.
  • the body 42 is a stent 48 including an annular ring 50, a first strut 52, and a second strut 54 (generally indicated).
  • the annular ring 50 acts as a base member to which the struts 52 and 54 are attached or otherwise extend from.
  • the annular ring 50 may be formed with a circular shape, in one embodiment, the preferred shape of the annular ring 50 is parabolic to more closely mimic the native mitral valve.
  • the first strut 52 extends from the annular ring 50 to a first rounded extremity or tip 56.
  • the second strut 54 is diametrically opposed to the first strut 52 and extends from the annular ring 50 to a second rounded extremity or tip 58.
  • the annular ring 50 defines a first relief 60 (generally indicated) between the struts 52 and 54 and a second relief 62 (generally indicated) between the struts 52 and 54 opposite the first relief 60.
  • Each relief 60 and 62 defines opposing smooth curves 64 and 66, respectively, adjacent to the respective struts 52 and 54 such that the reliefs 60 and 62 are each substantially arcuate in shape.
  • the struts 52 and 54 are depicted as being diametrically opposed, in other embodiments, the struts 52 and 54 are slightly offset from being truly diametrically opposed to one another (i.e., the second strut 54 is nonsymmetrically positioned relative to the first strut 52).
  • the first relief 60 has a longer length than the second relief 62 (or vice- versa) and later attachment utilizes a first leaflet 44 (Figure 3) being slightly larger than the second leaflet 46 ( Figure 3).
  • the differently sized leaflets 44 and 46 further mimic the natural sizing of native mitral valve leaflets.
  • the stent 48 is formed as an integral and homogeneous unit.
  • the stent 48 is made of discrete pieces subsequently joined together.
  • the stent 48 is made as slim and light as is compatible with the needed strength of the prosthetic valve 40 ( Figure 2) and to avoid the creation of sharp edges.
  • the annular ring 50 and the struts 52 and 54 are made of a slightly flexible, elastomeric material such as a synthetic plastic material including but not limited to polypropylene or acetal copolymer.
  • the amiular ring 50 and the struts 52 and 54 are formed of a thin wire or contoured thermoplastic material, e.g., polypropylene, celcon, or acetyl homopolymer.
  • the annular ring 50 and the struts 52 and 54 are formed of a metal material including, but not limited to, Eligiloy®, stainless steel, nitinol®, etc.
  • the struts 52 and 54 are formed of stiff but resiliently bendable material which allows the rounded extremities 56 and 58 of the struts 52 and 54 to deflect inward upon application of an external force, such as the force of a holder (not shown) used to insert the prosthetic valve 40 into the heart valve annulus.
  • an external force such as the force of a holder (not shown) used to insert the prosthetic valve 40 into the heart valve annulus.
  • the struts 52 and 54 Upon removal of the external force, the struts 52 and 54 are adapted to return to the original position as illustrated in Figure 4.
  • the stent 48 further includes a cloth covering 70, which covers and is sutured to and around the annular ring 50 and the struts 52 and 54.
  • the annular ring 50 and the struts 52 and 54 each defines one or a plurality of apertures (not shown) to facilitate suturing the covering 70 to the annular ring 50 and the struts 52 and 54.
  • the covering 70 is preferably formed of a biocompatible, fabric material.
  • the covering 70 is a porous, woven or knitted polytetrafluoroethylene (such as that sold under the tradename Teflon®) or polyester (such as that sold under the tradename Dacron®).
  • a suture ring 72 is coupled with the stent 48 to facilitate subsequent suturing of the prosthetic valve 40 to a heart valve annulus (not shown).
  • the suture ring 72 is formed of a tubular cloth covering 74, which is similar to the cloth covering 70 attached to the stent 48.
  • the cloth covering 74 is sutured to the cloth covering 70 of the stent 48 about the outer perimeter of the annular ring 50 opposite the extension of the struts 52 and 54.
  • the suture ring 72 further includes biocompatible cushion or stuffing material (not shown) disposed within the tubular cloth covering 74.
  • first leaflet 44 is a first left cusp 80, which is cut from a porcine aortic valve (not shown).
  • the left cusp 80 is cut from a porcine aortic valve examined and found inadequate for use in or as an aortic valve prosthesis.
  • the left cusp 80 can be cut from a porcine aortic valve that was otherwise rejected for possible use as an aortic valve prosthesis, hi particular, upon selection of a left cusp 80 for use in the prosthetic valve 40, the selected left cusp 80 is treated to fix and sterilize the valve tissue as well as to decrease the antigenicity of the left cusp 80. hi one embodiment, the left cusp 80 undergoes cross- linking using glutaraldehyde. However, in other embodiments, alternative chemistries are used to cross-link the first left cusp 80. After treatment, the left cusp 80 is cut from the remainder of a first porcine aortic valve for use in the prosthetic valve 40, resulting in the first leaflet 44.
  • the first leaflet 44 is elongated or generally "D" shaped and defines a cut edge 82, a free edge 84, a first attachment edge 86, and a second attachment edge 88.
  • the cut edge 82 was formally attached to and part of the first porcine aortic valve (not shown), and was cut in harvest of the first left cusp 80 from the first porcine aortic valve.
  • the free edge 84 is opposite the cut edge 82. As part of the porcine aortic valve, the free edge 84 was unattached and free to periodically coapt with the other aortic cusps (not shown).
  • the first and second attachment edges 86 and 88 run between the cut edge 82 and the free edge 84 opposite one another, and were also cut in harvest of the first left cusp 80 from the first porcine aortic valve.
  • the first attachment edge 86 further defines a first commissure portion 90 near the free edge 84.
  • the second attachment edge 88 defines a second commissure portion 92 near the free edge 84.
  • the first leaflet 44 defines an inner surface 94 and an outer surface 96 ( Figures 2 and 6) opposite the inner surface 94.
  • the second leaflet 46 is preferably a second left cusp 100, which is similar to the first left cusp 80 described above.
  • the second left cusp 100 is cut from the remainder of a second porcine aortic valve (not shown). Further, the second left cusp 100 is treated to fix and sterilize the tissue as well as to decrease the antigenicity of the second left cusp 100 as described above with respect to the first leaflet 44 (Fig. 5A).
  • the second leaflet 46 is elongated or generally "D" shaped and defines a cut edge 102, a free edge 104, a first attachment edge 106, and a second attachment edge 108 similar to the cut edge 82, the free edge 84, the first attachment edge 86, and the second attachment edge 88 of the first leaflet 44, respectively.
  • the first attachment edge 106 defines a first commissure portion 110 near the free edge 104.
  • the second attachment edge 108 defines a second commissure portion 112 near the free edge 104.
  • the second leaflet 46 defines an inner surface 114 and an outer surface 116 ( Figure 2) opposite the inner surface 114.
  • the first leaflet 44 and the second leaflet 46 are substantially similar in size.
  • the first leaflet 44 is slightly larger than the second leaflet 46.
  • the leaflets 44 and 46 are formed of other tissue, such as porcine, bovine, or human pericardium, fascia lata, and dura mater.
  • the leaflets 44 and 46 are, however, formed or cut from the tissue to define elongated or "D" shapes similar to the shape of the first and second left cusps 80 and 100 described above, rather than the typical circular leaflet shape.
  • the cut edge 102, the first attachment edge 106, and the second attachment edge 108 ( Figure 5B) of the selected second leaflet 46 are all sutured to the stent 48.
  • the second leaflet 46 is substantially centered with respect to the second relief 62 of the annular ring 50.
  • the cut edge 102 of second leaflet 46 is sutured to the covering 70 of the annular ring 50 at or below the second relief 62.
  • the first attachment edge 106 extends along and is sutured to the covering 70 over the interior side of the second strut 54.
  • the first attachment edge 106 is sutured to the second strut 54 such that the first commissure portion 110 is positioned substantially on a vertical centerline of the second strut 54.
  • the second attachment edge 108 similarly extends along and is sutured to the first strut 52. i one embodiment, the second attachment edge 108 is sutured to the covering 70 over the interior side of the first strut 52 such that the second commissure portion 112 ( Figure 5B) is positioned substantially on the vertical centerline of the first strut 52.
  • second leaflet 46 is attached to the stent 48 on all edges 102, 106, and 108 but the free edge 104.
  • the free edge 104 remains unsutured and extends between the extremities 56 and 58 of the struts 52 and 54.
  • the free edge 104 can freely transition between an open and a closed position.
  • the free edge 104 hangs near but above a catenary 120 defined between the extremities 56 and 58 of the struts 52 and 54.
  • the catenary 120 is an invisible curve representing the line of interaction between the leaflets 44 and 46 nearest the annular frame 50.
  • the free edge 104 of the second leaflet 46 has a length that is longer than a length of the catenary 120 between extremities 56 and 58.
  • the free edge 104 extends from the annular ring 50 in a substantially semi-annular manner.
  • the cut edge 82, the first attachment edge 86 ( Figure 5A), and the second attachment edge 88 of the first left leaflet 44 are sutured to the stent 48 of the prosthetic valve 40.
  • the first leaflet 44 is substantially centered with respect to the first relief 60 ( Figure 4) of the annular ring 50 as described and illustrated with respect to the second leaflet 46 and second relief 62.
  • the cut edge 82 and is sutured to the covering 70 at or below the first relief 60.
  • the first attachment edge 86 extends along and is sutured to the covering 70 over the interior side of the first strut 52 in a similar manner as described for second attachment edge 108.
  • the first attachment edge 86 is sutured to the first strut 52 such that the first commissure portion 90 is positioned substantially on the vertical centerline of the first strut 52.
  • the second attachment edge 88 extends along and is sutured to the covering 70 over the interior side of the second strut 54.
  • the second attachment edge 88 is sutured to the second strut 54 such that the second commissure portion 92 is positioned substantially on the vertical centerline of the second strut 54.
  • the first leaflet 44 is attached to the stent 48 on all the edges 82, 86, and 88 but the In a preferred embodiment, the first leaflet 44 and the second leaflet 46 are sutured to the first strut 52 such that the second commissure portion 92 of the sutured first leaflet 44 is positioned adjacent to the first commissure portion 110 of the sutured second leaflet 46.
  • first leaflet 44 and the second leaflet 46 are sutured to the first strut 52 such that the attachment edges 86 and 108 of the leaflets 44 and 46 are only positioned adjacent one another along the second commissure portion 92 of the first leaflet 44 and the first commissure portion 110 of the second leaflet 46.
  • first commissure portion 90 ( Figure 5 A) of the sutured first leaflet 44 is positioned on the second strut 54 adjacent to the second commissure portion 112 ( Figure 5B) of the sutured second leaflet 46.
  • other variations of suturing the leaflets 44 and 46 to the first and second struts 52 and 54 will be apparent to those of ordinary skill in the art.
  • the free edge 84 remains unsutured and extends between the extremities 56 and 58 of the struts 52 and 54. As such, the free edge 84 can freely transition between an open and a closed position. In particular, when in the closed position, the free edge 84 hangs near but above the catenary 120 defined between the extremities 56 and 58 of the struts 52 and 54 as best illustrated in Figure 2. Notably, the free edge 84 of the first leaflet 44 has a length, which is longer than a length of the catenary 120 between the extremities 56 and 58. When in the open position, illustrated in Figure 3, the free edge 84 extends from trie annular ring 50 in a substantially semi-annular manner.
  • the leaflets 44 and 46 are positioned and tightly and substantially continuously sutured to the stent 48 such that all seams or connections points between the leaflets 44 and 46 and the stent 48 substantially prevent blood flow from traveling through or escaping from the seams.
  • no blood flow escapes or passes through a properly implanted prosthetic valve 40 in the closed position.
  • the inner surfaces 94 and 114 Figure 3) of the first leaflet 44 and the second leaflet 46, respectively, interact or more precisely coapt with one another along and above the catenary 120.
  • each of the free edges 84 and 104 is slightly puckered or gathered.
  • first inner surface 94 and the second inner surface 114 redundantly coapt, or tightly interact to close about the catenary 120 and at a plurality of areas between the catenary 120 and the free edges 84 and 104.
  • substantial portions of the inner surface 94 of the first leaflet 44 and the inner surface 114 of the second leaflet 46 between the portion that coapts about the catenary 120 and the free edges 84 and 104 interact to form an enhanced area interface as compared to prior art leaflets that coapt only along a single catenary (see Figures 1 A and IB).
  • the redundant coaptation of, or repetitious interaction between, the leaflets 44 and 46 increases the integrity of the closure of the bileaflet, prosthetic valve 40.
  • the redundant coaptation not only mimics the native mitral valve, but also provides a robust seal between the two leaflets 44 and 46 during closure, to prevent leakage through the prosthetic valve 40 during closure.
  • the benefit of the additional closure integrity is increased due to the prolonged closure periods and the relatively high pressures to be experienced by the prosthetic valve 40 upon implant within a patient.
  • the free edges 84 and 104 each extend from the annular ring 50 in a semi-annular manner such that the prosthetic valve 40 merely forms a substantially tubular cavity for blood flow to travel through.
  • the length of the first free edge 84 is longer than the length of the catenary 120.
  • the length of the second free edge 104 is greater than the length of the catenary 120.
  • an opening 122 is formed having a perimeter substantially equal to the sum of the length of the first free edge 84 and the length of the second free edge 104. Otherwise stated, the opening 122 is formed having a perimeter greater than double the length of the catenary 120.
  • the relatively large opening as compared to the opening of the prior art prosthetic mitral valves, allows blood to flow through the prosthetic valve 40 with a lessened degree of obstruction.
  • the prosthetic valve 40 can be manufactured in a plurality of sizes to provide replacement valves for the plurality of annulus sizes found in heart valve replacement patients.
  • the prosthetic valve 40 is manufactured in a plurality of sizes to provide replacement valves for mitral valves, aortic valves, tricuspid valves, and pulmonary valves.
  • the maximum diameter of the bileaflet prosthetic mitral valve range from approximately 25 mm to 35 mm.
  • a first left cusp 80 and a second left cusp 100 are selected to correspond with the size of the particular stent 48 of the prosthetic valve 40 being manufactured.
  • the prosthetic valve 40 is implanted and sutured to the heart valve annulus of the mitral valve (not shown).
  • a surgeon sutures the suture ring 72 to the annulus ledge or within the annulus opening depending upon the implantation technique (intra-annular or supra-annular) being utilized for the particular heart valve replacement surgery.
  • the prosthetic valve 40 is implanted through a catheter.
  • the two leaflet nature of the prosthetic valve 40 may make the prosthetic valve 40 more compressible and, therefore, even more conducive to catheter implantation than its three leaflet counterparts.
  • the prosthetic valve 40 is implanted without the use of a catheter.
  • the prosthetic valve 40 is a bileaflet valve that opens widely and closes incorporating redundant coaptation in a manner similar to the native mitral valve. Although described as replacing a mitral valve, the prosthetic valve 40 can be used in valve replacement surgery for an aortic valve, a tricuspid valve, or a pulmonary valve.
  • Figures 6 and 7 illustrate another embodiment of a bileaflet prosthetic valve generally indicated at 130.
  • the prosthetic valve 130 includes a body 132, the first leaflet 44, and the second leaflet 46.
  • the body 132 is tubular and, in one embodiment, is round or parabolic (i.e., elongated) in shape, i one embodiment, the tubular body 132 is formed of one of the following: a porcine tissue, a pericardial tissue, a venous material, a cloth, or a mesh material. In one embodiment, the tubular body 132 is a porcine aortic root.
  • Each of the first and second leaflets 44 and 46 are sized and selected to correspond with the size of the tubular body 132.
  • the first and second leaflets 44 and 46 are attached to the tubular body 132 in a similar manner as leaflets 44 and 46 are attached to the stent 48.
  • the cut edge 82, the first attachment edge 86, and the second attachment edge 88 of the first leaflet 44 are all sutured to an inner surface 134 of the tubular body 132.
  • the cut edge 102, the first attachment edge 106, and the second attachment edge 108 of the second leaflet 46 are sutured to the inner surface 134 of the tubular body 132.
  • the cut edges 82 and 102 are attached by suture to the inner surface 134 opposite one another and along a bottom circumference (not shown) of the inner surface 134.
  • the attachment edges 86, 88, 106, and 108 extend away from the cut edges 82 and 102 and are sutured to the inner surface 134.
  • the leaflets 44 and 46 are sutured to the inner surface 134 such that the commissure 92 of the second edge 88 is positioned adjacent the commissure portion 110 of the first edge 106.
  • the leaflets 44 and 46 are sutured such that the commissure portion 90 of the first edge 86 is positioned adjacent the commissure portion 112 of the second edge 108.
  • the free edges 84 and 104 remain unsutured to freely transition between an open and a closed position as described above with respect to prosthetic valve 40.
  • the leaflets 44 and 46 are configured and attached to the tubular body 132 such that the inner surfaces 94 and 114 of the leaflets 44 and 46 redundantly interact or, more precisely, coapt with one another along and above a catenary 140, which, extends between the commissure portions 92 and 100 and the commissure portions 90 and 112.
  • the free edges 84 and 104 each have a length longer than a length of the catenary 140.
  • the prosthetic valve 130 can be manufactured in a plurality of sizes to provide replacement valves for a plurality of annulus sizes found in heart valve replacement patients.
  • the prosthetic valve 130 is manufactured in a plurality of sizes to provide replacement valves for mitral valves, aortic valves, tricuspid valves, and pulmonary valves.
  • the prosthetic valve 130 is implanted in a similar manner as described above with respect to the prosthetic valve 40.
  • the tubular body 132 is placed within the annulus opening (not shown) and sutured to the annulus edge or within the annulus opening depending upon the implantation technique being utilized for the particular heart valve replacement surgery.
  • a prosthetic, bileaflet valve according to the present invention is shaped substantially similar to and substantially mimics the functioning of the native mitral valve.
  • the bileaflet valve prosthetic includes cusps or leaflets having a longer free edge than the catenary in which they originally coapt.
  • the opening periodically formed by the bileaflet valve is not limited in size or cross-section due to the length of the catenary. Rather, the bileaflet valve of the present invention opens widely, to cause less obstruction of blood flow than prior art valve prosthetics. Less obstruction of blood flow directly correlates to increased valve durability as well as increased post-operative patient activity and overall patient well being.
  • the bileaflet valve of the present invention redundantly coapts similar to the native mitral valve.
  • the redundant coaptation ensures a better seal of the closed valve, which is especially important under the relatively high pressure and long closure periods of the mitral valve.
  • the high integrity closure prevents or decreases blood leakage through the bileaflet valve while the bileaflet valve is in the closed position. Decreasing undesired leakage of the bileaflet valve decreases complications associated with heart valve replacement surgery as well contributes to the overall well being of the patient.

Abstract

A prosthetic valve (40) including a body (42), a first leaflet (44), and a second leaflet (46). The first leaflet extends across and is coupled to the body. The first leaflet is cut from a first porcine aortic valve and defines a first inner surface (94). The second leaflet extends across and is coupled to the body opposite the first leaflet. The second leaflet is cut from a second porcine aortic valve and defines a second inner surface (114).

Description

BILEAFLET PROSTHETIC VALVE AND METHOD OF MANUFACTURE
Background of the Invention The present invention relates to an implantable prosthetic valve. More particularly, the present invention relates to a bileaflet implantable prosthetic valve with redundant coaptation to be implanted during heart valve replacement surgery. There are four valves of the heart, the mitral valve, the aortic valve, the tricuspid valve, and the pulmonary valve. Anatomically and generally speaking, each valve forms or defines a valve annulus and valve leaflets. Although similar in general function, the mitral valve differs significantly in anatomy from the other valves, in particular, the aortic valve. The annulus of the mitral valve is somewhat "D" shaped or elongated whereas the annulus of the aortic valve is more nearly circular. Furthermore, the mitral valve includes two leaflets that are oval or "D" shaped, in contrast to the aortic valve, which includes three leaflets that are more nearly circular. Mitral valves are also subject to higher pressure and longer closure periods than are aortic valves. To accommodate such conditions, native mitral valves incorporate redundant coaptation. The term "redundant coaptation" is used to refer to closure of the valve at more than one line of interaction between the leaflets. In particular, the native mitral valve leaflets interact during closure tightly mating or coapting along a first line. In addition, the native mitral valve leaflets also interact or coapt at multiple points between the first line and the free edges of the leaflets (i.e., the edges of the leaflets not attached to the remaining valve). Moreover, the native mitral valve leaflets, close to interact or coapt with one another such that the free edges are gathered or puckered rather than held substantially taut. The repetitious or redundant coaptation bolsters the integrity of the valve to better maintain closure during relatively long periods and to better withstand the high closure pressures. Any heart valve can be subjected to or incur damage that requires the valve to be repaired or replaced. A majority of patients with heart valve disease undergo heart valve replacement surgery rather than heart valve repair. Various types and configurations of prosthetic heart valves are used to replace diseased, human heart valves. In general terms, the prosthetic heart valve design attempts to replicate the function of the valve being replaced and thus will include valve or leaflet-like structures. With this in mind, prosthetic heart valves are generally classified as either forming relatively rigid leaflets or forming relatively flexible leaflets. The category including prosthetic heart valves which form relatively flexible leaflets includes bioprosthetic heart valves having leaflets made of a biological material as well as prosthetic heart valves having leaflets made of synthetic (e.g., polymeric) material. Flexible leaflet prosthetic heart valves are generally categorized as having a frame or a stent or as having no stent. Despite the different anatomies of the different heart valves described above, conventional, flexible leaflet, prosthetic heart valves designed for use with the different heart valves are surprisingly similar. In particular, in creating flexible leaflet, prosthetic heart valves using porcine tissue for leaflets, the porcine aortic valve is typically used to make both the aortic and mitral prosthetic valves. More commonly, a single type of prosthetic porcine valve is manufactured and used for replacement of both the aortic and mitral valves. The aortic porcine valve is circular, similar to the native human aortic valve. However, as previously described, the native human mitral valve is more oval or elongated than circular. Therefore, during implantation, the typical mitral valve prosthetic made from a porcine aortic valve must be forced to conform to the non-circular annulus of the native mitral valve. In addition to the different overall valve shapes, a porcine aortic valve and the resulting prosthetic valves each have three leaflets while a native mitral valve has only two leaflets. Moreover, the conventional tri-leaflet prosthetic valves do not incorporate redundant coaptation while closed and, therefore, such prosthetic valves are not specifically designed to withstand the higher pressures and longer closure periods experienced by the mitral valve. As such, the anatomy of the prosthetic valves typically used to replace a mitral valve do not sufficiently replicate the native mitral valve anatomy. More recently, flexible leaflet, prosthetic valves have been developed incorporating the bileaflet anatomy of the native mitral valve. In particular, Figures 1 A and IB illustrate a prior art bileaflet, prosthetic valve generally at 10. The conventional prosthetic valve 10 includes a stent 12 (generally indicated), a first leaflet 14, and a second leaflet 16. The stent 12 defines an annular ring 18, a first strut 20, and a second strut 22. The first strut 20 is coupled with and extends from the annular ring 18 to form a rounded tip 24. The second strut 22 is diametrically opposed to the first strut 20 and is coupled with and extends from the annular ring 18 to form a rounded tip 26. The first leaflet 14 is coupled with the stent 12 by suturing the first leaflet 14 to the annular ring 18 and the first and second struts 20 and 22. As such, the first leaflet 14 extends between the struts 20 and 22 to define a free edge 30 opposite the annular ring 18. Similarly, the second leaflet 16 is coupled with the stent 12 by suturing the second leaflet 16 to the annular ring 18 and the struts 20 and 22. Therefore, the second leaflet 16 extends between the struts 20 and 22 opposite the first leaflet 14 to define a free edge 32 opposite the annular ring 18. As illustrated in Figure 1 A, the prosthetic valve 10 closes such that the free edge 30 and the free edge 32 coapt or fit together to tightly close the prosthetic valve 10. In particular, the free edges 30 and 32 directly abut one another in the closed position. Notably, the intersection between the free edges 30 and 32 defines a catenary 34 between the first tip 24 of the first strut 20 and the second tip 26 of the second strut 22. The catenary 34 is more precisely an imaginary curve that extends between and, in effect, hangs from, the first tip 24 and the second tip 26. In the case of the prosthetic valve 10, the catenary 34 represents the first and only line of interaction between the first and second leaflets 14 and 16 during closure. When in the closed position, the first leaflet 14 and the second leaflet 16 are each maintained in a relatively taut manner. As illustrated by comparison of Figures 1A and IB, to open the prosthetic valve 10, the free edge 30 of the first leaflet 14 transitions away from the catenary 34 in a direction opposite the free edge 32 of the second leaflet 16. Simultaneously, the free edge 32 of the second leaflet 16 transitions away from the catenary 34 in a direction opposite the free end 30. Accordingly, when in an open position, the prosthetic valve 10 forms an open cavity for blood to flow through. Notably, upon opening (FIG. IB), each of the free edges 30 and 32 has a length equal to the length of the catenary 34 (FIG. 1 A). » Accordingly, upon opening, the prosthetic mitral valve 10, more particularly the free edges 30 and 32, form an opening 36 having a perimeter substantially equal to twice the length of the catenary 34. As such, the length of the catenary 34 limits the size of the opening 36, which may impede blood flow through the valve prosthetic 10. Conventional flexible leaflet, prosthetic valves having no stent typically are tri- leaflet valves that tightly coapt such that the free edges of each leaflet abut one another upon closure of the stentless valve. Often, an entirety (i.e., the valve annulus and leaflets) of a porcine aortic valve is harvested, treated, and used as the replacement valve in heat valve replacement surgery. However, similar to the conventional stented valves, conventional stentless valves are not constructed or modified to withstand relatively high pressures and prolonged closing intervals. As described above, upon closure, the leaflets of a typical prosthetic valves are maintained in a relatively taut manner. The taut leaflets are in contrast to the puckered leaflets of the native mitral valve, which provide for redundant coaptation, a stronger valve closure, and a larger valve opening. As such, a need exists for a prosthetic valve that provides for a stronger valve closure and for a larger valve opening. In particular, a need exists for a prosthetic valve that is more adept to high pressures and prolonged closing times.
Summary of the Invention One aspect of the present invention relates to a prosthetic valve including a body, a first leaflet, and a second leaflet. The first leaflet extends across and is coupled to the body. The first leaflet is cut from a first porcine aortic valve and defines a first inner surface. The second leaflet extends across and is coupled to the body opposite the first leaflet. The second leaflet is cut from a second porcine aortic valve and defines a second inner surface. Another aspect of the present invention relates to a prosthetic valve including a body, a first leaflet, and a second leaflet. The first leaflet extends across and is sutured to the body. The first leaflet has an elongated shape. The second leaflet extends across and is sutured to the body opposite the first leaflet. The second leaflet has an elongated shape. Another aspect of the present invention relates to a prosthetic valve including a body, a first leaflet, and a second leaflet. The first leaflet extends across and is sutured to the body. The first leaflet is cut from a first porcine aortic valve, defines a first inner surface, and has an elongated shape. The second leaflet extends across and is sutured to the body opposite the first leaflet. The second leaflet is cut from a second porcine aortic valve, defines a second inner surface, and has an elongated shape. Yet another aspect of the present invention relates to a method of manufacturing a prosthetic mitral valve. The method includes providing a body, cutting a first leaflet defining a first inner surface from a first porcine aortic valve, coupling the first leaflet to the body, cutting a second leaflet defining a second inner surface from a second porcine aortic valve, and coupling the second leaflet to the body opposite the first leaflet.
Brief Description of the Drawings Figure 1 A is a perspective view of a prior art prosthetic valve in a closed position; Figure IB is a perspective view of the prior art prosthetic valve illustrated in Figure 1 A in an open position; Figure 2 is a perspective view of one embodiment of a bileaflet prosthetic valve in a closed position in accordance with the present invention; Figure 3 is a perspective view of the bileaflet prosthetic valve illustrated in Figure 2 in an opened position; Figure 4 is a perspective view of one embodiment of a stent and a cloth covering of the bileaflet prosthetic valve illustrated in Figure 2; Figure 5 A is a schematic view of one embodiment of a left cusp of a porcine aortic valve for use in the bileaflet prosthetic valve illustrated in Figure 2; Figure 5B is a schematic view of one embodiment of another left cusp of a porcine aortic valve for use in the bileaflet prosthetic valve illustrated in Figure 2; Figure 6 is a perspective view of one embodiment of a stentless, bileaflet prosthetic valve according to the present invention; and Figure 7 is a top view of the stentless, bileaflet prosthetic valve of Figure 6.
Detailed Description of the Preferred Embodiments One preferred embodiment of a bileaflet, prosthetic valve 40 in accordance with the present invention is illustrated in Figures 2 and 3. The prosthetic valve 40 includes a body 42, a first leaflet 44, and a second leaflet 46. The body 42 serves as the support structure to which the first leaflet 44 and the second leaflet 46 are opposingly attached. In particular, the leaflets 44 and 46 are attached such that in a closed position, as illustrated in Figure 2, the first leaflet 44 interacts with the second leaflet 46 to close the prosthetic valve 40. More precisely, the first leaflet 44 and the second leaflet 46 redundantly coapt to close and to prevent blood flow through the prosthetic valve 40prosthetic valve 40. When open, as illustrated in Figure 3, the first leaflet 44 and the second leaflet 46 are pulled away from one another, thereby opening the prosthetic valve 40 to allow blood flow to freely pass through the prosthetic valve 40. As illustrated in Figure 4, in one embodiment, the body 42 is a stent 48 including an annular ring 50, a first strut 52, and a second strut 54 (generally indicated). The annular ring 50 acts as a base member to which the struts 52 and 54 are attached or otherwise extend from. Although the annular ring 50 may be formed with a circular shape, in one embodiment, the preferred shape of the annular ring 50 is parabolic to more closely mimic the native mitral valve. The first strut 52 extends from the annular ring 50 to a first rounded extremity or tip 56. Similarly, the second strut 54 is diametrically opposed to the first strut 52 and extends from the annular ring 50 to a second rounded extremity or tip 58. The annular ring 50 defines a first relief 60 (generally indicated) between the struts 52 and 54 and a second relief 62 (generally indicated) between the struts 52 and 54 opposite the first relief 60. Each relief 60 and 62 defines opposing smooth curves 64 and 66, respectively, adjacent to the respective struts 52 and 54 such that the reliefs 60 and 62 are each substantially arcuate in shape. Although the struts 52 and 54 are depicted as being diametrically opposed, in other embodiments, the struts 52 and 54 are slightly offset from being truly diametrically opposed to one another (i.e., the second strut 54 is nonsymmetrically positioned relative to the first strut 52). In such an embodiment, the first relief 60 has a longer length than the second relief 62 (or vice- versa) and later attachment utilizes a first leaflet 44 (Figure 3) being slightly larger than the second leaflet 46 (Figure 3). In one embodiment, the differently sized leaflets 44 and 46 further mimic the natural sizing of native mitral valve leaflets. In one embodiment, the stent 48 is formed as an integral and homogeneous unit. In an alternative embodiment, the stent 48 is made of discrete pieces subsequently joined together. Preferably, the stent 48 is made as slim and light as is compatible with the needed strength of the prosthetic valve 40 (Figure 2) and to avoid the creation of sharp edges. In one embodiment, the annular ring 50 and the struts 52 and 54 are made of a slightly flexible, elastomeric material such as a synthetic plastic material including but not limited to polypropylene or acetal copolymer. In another embodiment, the amiular ring 50 and the struts 52 and 54 are formed of a thin wire or contoured thermoplastic material, e.g., polypropylene, celcon, or acetyl homopolymer. hi one embodiment, the annular ring 50 and the struts 52 and 54 are formed of a metal material including, but not limited to, Eligiloy®, stainless steel, nitinol®, etc. Preferably, the struts 52 and 54 are formed of stiff but resiliently bendable material which allows the rounded extremities 56 and 58 of the struts 52 and 54 to deflect inward upon application of an external force, such as the force of a holder (not shown) used to insert the prosthetic valve 40 into the heart valve annulus. Upon removal of the external force, the struts 52 and 54 are adapted to return to the original position as illustrated in Figure 4. Preferably, the stent 48 further includes a cloth covering 70, which covers and is sutured to and around the annular ring 50 and the struts 52 and 54. In one embodiment, the annular ring 50 and the struts 52 and 54 each defines one or a plurality of apertures (not shown) to facilitate suturing the covering 70 to the annular ring 50 and the struts 52 and 54. The covering 70 is preferably formed of a biocompatible, fabric material. In one embodiment, the covering 70 is a porous, woven or knitted polytetrafluoroethylene (such as that sold under the tradename Teflon®) or polyester (such as that sold under the tradename Dacron®). In one embodiment, a suture ring 72 is coupled with the stent 48 to facilitate subsequent suturing of the prosthetic valve 40 to a heart valve annulus (not shown). The suture ring 72 is formed of a tubular cloth covering 74, which is similar to the cloth covering 70 attached to the stent 48. The cloth covering 74 is sutured to the cloth covering 70 of the stent 48 about the outer perimeter of the annular ring 50 opposite the extension of the struts 52 and 54. In one embodiment, the suture ring 72 further includes biocompatible cushion or stuffing material (not shown) disposed within the tubular cloth covering 74. In one embodiment, the suture ring 72 further includes an additional support ring (not shown) disposed within the cloth covering 74 to provide additional support to the prosthetic valve 40. Figure 5 A illustrates one embodiment of the first leaflet 44. Preferably, first leaflet 44 is a first left cusp 80, which is cut from a porcine aortic valve (not shown). In one embodiment, the left cusp 80 is cut from a porcine aortic valve examined and found inadequate for use in or as an aortic valve prosthesis. As such, the left cusp 80 can be cut from a porcine aortic valve that was otherwise rejected for possible use as an aortic valve prosthesis, hi particular, upon selection of a left cusp 80 for use in the prosthetic valve 40, the selected left cusp 80 is treated to fix and sterilize the valve tissue as well as to decrease the antigenicity of the left cusp 80. hi one embodiment, the left cusp 80 undergoes cross- linking using glutaraldehyde. However, in other embodiments, alternative chemistries are used to cross-link the first left cusp 80. After treatment, the left cusp 80 is cut from the remainder of a first porcine aortic valve for use in the prosthetic valve 40, resulting in the first leaflet 44. The first leaflet 44 is elongated or generally "D" shaped and defines a cut edge 82, a free edge 84, a first attachment edge 86, and a second attachment edge 88. The cut edge 82 was formally attached to and part of the first porcine aortic valve (not shown), and was cut in harvest of the first left cusp 80 from the first porcine aortic valve. The free edge 84 is opposite the cut edge 82. As part of the porcine aortic valve, the free edge 84 was unattached and free to periodically coapt with the other aortic cusps (not shown). The first and second attachment edges 86 and 88 run between the cut edge 82 and the free edge 84 opposite one another, and were also cut in harvest of the first left cusp 80 from the first porcine aortic valve. The first attachment edge 86 further defines a first commissure portion 90 near the free edge 84. Similarly, the second attachment edge 88 defines a second commissure portion 92 near the free edge 84. The first leaflet 44 defines an inner surface 94 and an outer surface 96 (Figures 2 and 6) opposite the inner surface 94. As illustrated in Figure 5B, the second leaflet 46 is preferably a second left cusp 100, which is similar to the first left cusp 80 described above. In particular, the second left cusp 100 is cut from the remainder of a second porcine aortic valve (not shown). Further, the second left cusp 100 is treated to fix and sterilize the tissue as well as to decrease the antigenicity of the second left cusp 100 as described above with respect to the first leaflet 44 (Fig. 5A). The second leaflet 46 is elongated or generally "D" shaped and defines a cut edge 102, a free edge 104, a first attachment edge 106, and a second attachment edge 108 similar to the cut edge 82, the free edge 84, the first attachment edge 86, and the second attachment edge 88 of the first leaflet 44, respectively. The first attachment edge 106 defines a first commissure portion 110 near the free edge 104. Accordingly, the second attachment edge 108 defines a second commissure portion 112 near the free edge 104. The second leaflet 46 defines an inner surface 114 and an outer surface 116 (Figure 2) opposite the inner surface 114. Preferably, the first leaflet 44 and the second leaflet 46 are substantially similar in size. In one embodiment, the first leaflet 44 is slightly larger than the second leaflet 46. In alternative embodiments, the leaflets 44 and 46 are formed of other tissue, such as porcine, bovine, or human pericardium, fascia lata, and dura mater. In such embodiments, the leaflets 44 and 46 are, however, formed or cut from the tissue to define elongated or "D" shapes similar to the shape of the first and second left cusps 80 and 100 described above, rather than the typical circular leaflet shape. As illustrated in Figure 3, during manufacture, the cut edge 102, the first attachment edge 106, and the second attachment edge 108 (Figure 5B) of the selected second leaflet 46 are all sutured to the stent 48. In particular, the second leaflet 46 is substantially centered with respect to the second relief 62 of the annular ring 50. The cut edge 102 of second leaflet 46 is sutured to the covering 70 of the annular ring 50 at or below the second relief 62. The first attachment edge 106 extends along and is sutured to the covering 70 over the interior side of the second strut 54. In one embodiment, the first attachment edge 106 is sutured to the second strut 54 such that the first commissure portion 110 is positioned substantially on a vertical centerline of the second strut 54. Although not illustrated, the second attachment edge 108 similarly extends along and is sutured to the first strut 52. i one embodiment, the second attachment edge 108 is sutured to the covering 70 over the interior side of the first strut 52 such that the second commissure portion 112 (Figure 5B) is positioned substantially on the vertical centerline of the first strut 52. As such, second leaflet 46 is attached to the stent 48 on all edges 102, 106, and 108 but the free edge 104. The free edge 104 remains unsutured and extends between the extremities 56 and 58 of the struts 52 and 54. As such, the free edge 104 can freely transition between an open and a closed position. In particular, when in the closed position, the free edge 104 hangs near but above a catenary 120 defined between the extremities 56 and 58 of the struts 52 and 54. The catenary 120 is an invisible curve representing the line of interaction between the leaflets 44 and 46 nearest the annular frame 50. Notably, the free edge 104 of the second leaflet 46 has a length that is longer than a length of the catenary 120 between extremities 56 and 58. When in the open position, as best illustrated in Figure 3, the free edge 104 extends from the annular ring 50 in a substantially semi-annular manner. During manufacture, the cut edge 82, the first attachment edge 86 (Figure 5A), and the second attachment edge 88 of the first left leaflet 44 are sutured to the stent 48 of the prosthetic valve 40. In particular, the first leaflet 44 is substantially centered with respect to the first relief 60 (Figure 4) of the annular ring 50 as described and illustrated with respect to the second leaflet 46 and second relief 62. The cut edge 82 and is sutured to the covering 70 at or below the first relief 60. Although not fully illustrated, the first attachment edge 86 extends along and is sutured to the covering 70 over the interior side of the first strut 52 in a similar manner as described for second attachment edge 108. In one embodiment, the first attachment edge 86 is sutured to the first strut 52 such that the first commissure portion 90 is positioned substantially on the vertical centerline of the first strut 52. The second attachment edge 88 extends along and is sutured to the covering 70 over the interior side of the second strut 54. i one embodiment, the second attachment edge 88 is sutured to the second strut 54 such that the second commissure portion 92 is positioned substantially on the vertical centerline of the second strut 54. As such the first leaflet 44 is attached to the stent 48 on all the edges 82, 86, and 88 but the In a preferred embodiment, the first leaflet 44 and the second leaflet 46 are sutured to the first strut 52 such that the second commissure portion 92 of the sutured first leaflet 44 is positioned adjacent to the first commissure portion 110 of the sutured second leaflet 46. i one embodiment, the first leaflet 44 and the second leaflet 46 are sutured to the first strut 52 such that the attachment edges 86 and 108 of the leaflets 44 and 46 are only positioned adjacent one another along the second commissure portion 92 of the first leaflet 44 and the first commissure portion 110 of the second leaflet 46. Similarly although hidden in Figure 3, in a preferred embodiment, the first commissure portion 90 (Figure 5 A) of the sutured first leaflet 44 is positioned on the second strut 54 adjacent to the second commissure portion 112 (Figure 5B) of the sutured second leaflet 46. Notably, other variations of suturing the leaflets 44 and 46 to the first and second struts 52 and 54 will be apparent to those of ordinary skill in the art. The free edge 84 remains unsutured and extends between the extremities 56 and 58 of the struts 52 and 54. As such, the free edge 84 can freely transition between an open and a closed position. In particular, when in the closed position, the free edge 84 hangs near but above the catenary 120 defined between the extremities 56 and 58 of the struts 52 and 54 as best illustrated in Figure 2. Notably, the free edge 84 of the first leaflet 44 has a length, which is longer than a length of the catenary 120 between the extremities 56 and 58. When in the open position, illustrated in Figure 3, the free edge 84 extends from trie annular ring 50 in a substantially semi-annular manner. Upon assembly, the leaflets 44 and 46 are positioned and tightly and substantially continuously sutured to the stent 48 such that all seams or connections points between the leaflets 44 and 46 and the stent 48 substantially prevent blood flow from traveling through or escaping from the seams. Preferably, upon assembly, no blood flow escapes or passes through a properly implanted prosthetic valve 40 in the closed position. Following assembly, when the prosthetic valve 40 is in the closed position (Figure 2), the inner surfaces 94 and 114 (Figure 3) of the first leaflet 44 and the second leaflet 46, respectively, interact or more precisely coapt with one another along and above the catenary 120. However, the free edge 84 of the first leaflet 44 and the free edge 104 of the second leaflet 46 are not held taut near the catenary 120, nor do the free edge 84 and trie free edge 104 mate directly with one another. Rather, due to the excess tissue of each of the leaflets 44 and 46 and the fact that each of the free edges 84 and 104 has a length longer than the length of the catenary 120, upon closing, each of the free edges 84 and 104 is slightly puckered or gathered.
Further due to the extra tissue of each leaflet 44 and 46, as compared to the prior art, the first inner surface 94 and the second inner surface 114 redundantly coapt, or tightly interact to close about the catenary 120 and at a plurality of areas between the catenary 120 and the free edges 84 and 104. As such, substantial portions of the inner surface 94 of the first leaflet 44 and the inner surface 114 of the second leaflet 46 between the portion that coapts about the catenary 120 and the free edges 84 and 104 interact to form an enhanced area interface as compared to prior art leaflets that coapt only along a single catenary (see Figures 1 A and IB). Notably, the redundant coaptation of, or repetitious interaction between, the leaflets 44 and 46 increases the integrity of the closure of the bileaflet, prosthetic valve 40. The redundant coaptation not only mimics the native mitral valve, but also provides a robust seal between the two leaflets 44 and 46 during closure, to prevent leakage through the prosthetic valve 40 during closure. Moreover, the benefit of the additional closure integrity is increased due to the prolonged closure periods and the relatively high pressures to be experienced by the prosthetic valve 40 upon implant within a patient. Upon transition to an open position, and as best illustrated in Figure 3, the free edge 84 and the free edge 104 transition away from the catenary 120, opposite one another. When open, the free edges 84 and 104 each extend from the annular ring 50 in a semi-annular manner such that the prosthetic valve 40 merely forms a substantially tubular cavity for blood flow to travel through. Notably, as mentioned above, the length of the first free edge 84 is longer than the length of the catenary 120. Similarly, the length of the second free edge 104 is greater than the length of the catenary 120. As such, upon opening of the prosthetic valve 40, an opening 122 is formed having a perimeter substantially equal to the sum of the length of the first free edge 84 and the length of the second free edge 104. Otherwise stated, the opening 122 is formed having a perimeter greater than double the length of the catenary 120. The relatively large opening, as compared to the opening of the prior art prosthetic mitral valves, allows blood to flow through the prosthetic valve 40 with a lessened degree of obstruction. The prosthetic valve 40 can be manufactured in a plurality of sizes to provide replacement valves for the plurality of annulus sizes found in heart valve replacement patients. In one embodiment, the prosthetic valve 40 is manufactured in a plurality of sizes to provide replacement valves for mitral valves, aortic valves, tricuspid valves, and pulmonary valves. In one embodiment, the maximum diameter of the bileaflet prosthetic mitral valve range from approximately 25 mm to 35 mm. As such, prior to attachment, a first left cusp 80 and a second left cusp 100 are selected to correspond with the size of the particular stent 48 of the prosthetic valve 40 being manufactured. During use, the prosthetic valve 40 is implanted and sutured to the heart valve annulus of the mitral valve (not shown). In particular, a surgeon sutures the suture ring 72 to the annulus ledge or within the annulus opening depending upon the implantation technique (intra-annular or supra-annular) being utilized for the particular heart valve replacement surgery. In one embodiment, the prosthetic valve 40 is implanted through a catheter. Notably, the two leaflet nature of the prosthetic valve 40 may make the prosthetic valve 40 more compressible and, therefore, even more conducive to catheter implantation than its three leaflet counterparts. In other embodiments, the prosthetic valve 40 is implanted without the use of a catheter. The prosthetic valve 40 is a bileaflet valve that opens widely and closes incorporating redundant coaptation in a manner similar to the native mitral valve. Although described as replacing a mitral valve, the prosthetic valve 40 can be used in valve replacement surgery for an aortic valve, a tricuspid valve, or a pulmonary valve. Figures 6 and 7 illustrate another embodiment of a bileaflet prosthetic valve generally indicated at 130. The prosthetic valve 130 includes a body 132, the first leaflet 44, and the second leaflet 46. The body 132 is tubular and, in one embodiment, is round or parabolic (i.e., elongated) in shape, i one embodiment, the tubular body 132 is formed of one of the following: a porcine tissue, a pericardial tissue, a venous material, a cloth, or a mesh material. In one embodiment, the tubular body 132 is a porcine aortic root. Each of the first and second leaflets 44 and 46 are sized and selected to correspond with the size of the tubular body 132. The first and second leaflets 44 and 46 are attached to the tubular body 132 in a similar manner as leaflets 44 and 46 are attached to the stent 48. hi particular, with additional reference to Figures 5A and 5B, the cut edge 82, the first attachment edge 86, and the second attachment edge 88 of the first leaflet 44 are all sutured to an inner surface 134 of the tubular body 132. Similarly, the cut edge 102, the first attachment edge 106, and the second attachment edge 108 of the second leaflet 46 are sutured to the inner surface 134 of the tubular body 132. The cut edges 82 and 102 are attached by suture to the inner surface 134 opposite one another and along a bottom circumference (not shown) of the inner surface 134. The attachment edges 86, 88, 106, and 108 extend away from the cut edges 82 and 102 and are sutured to the inner surface 134. In one embodiment, the leaflets 44 and 46 are sutured to the inner surface 134 such that the commissure 92 of the second edge 88 is positioned adjacent the commissure portion 110 of the first edge 106. Similarly, the leaflets 44 and 46 are sutured such that the commissure portion 90 of the first edge 86 is positioned adjacent the commissure portion 112 of the second edge 108. The free edges 84 and 104 remain unsutured to freely transition between an open and a closed position as described above with respect to prosthetic valve 40. In particular, the leaflets 44 and 46 are configured and attached to the tubular body 132 such that the inner surfaces 94 and 114 of the leaflets 44 and 46 redundantly interact or, more precisely, coapt with one another along and above a catenary 140, which, extends between the commissure portions 92 and 100 and the commissure portions 90 and 112. Notably, the free edges 84 and 104 each have a length longer than a length of the catenary 140. Upon opening the free edges 84 and 104 define an opening (not shown) that is similar to the opening 122 (Figure 3) having a perimeter greater than double the length of the catenary 140. The prosthetic valve 130 can be manufactured in a plurality of sizes to provide replacement valves for a plurality of annulus sizes found in heart valve replacement patients. In one embodiment, the prosthetic valve 130 is manufactured in a plurality of sizes to provide replacement valves for mitral valves, aortic valves, tricuspid valves, and pulmonary valves. The prosthetic valve 130 is implanted in a similar manner as described above with respect to the prosthetic valve 40. Normally the tubular body 132 is placed within the annulus opening (not shown) and sutured to the annulus edge or within the annulus opening depending upon the implantation technique being utilized for the particular heart valve replacement surgery. In general, a prosthetic, bileaflet valve according to the present invention is shaped substantially similar to and substantially mimics the functioning of the native mitral valve. The bileaflet valve prosthetic includes cusps or leaflets having a longer free edge than the catenary in which they originally coapt. As such, the opening periodically formed by the bileaflet valve is not limited in size or cross-section due to the length of the catenary. Rather, the bileaflet valve of the present invention opens widely, to cause less obstruction of blood flow than prior art valve prosthetics. Less obstruction of blood flow directly correlates to increased valve durability as well as increased post-operative patient activity and overall patient well being. In addition, the bileaflet valve of the present invention redundantly coapts similar to the native mitral valve. The redundant coaptation ensures a better seal of the closed valve, which is especially important under the relatively high pressure and long closure periods of the mitral valve. The high integrity closure prevents or decreases blood leakage through the bileaflet valve while the bileaflet valve is in the closed position. Decreasing undesired leakage of the bileaflet valve decreases complications associated with heart valve replacement surgery as well contributes to the overall well being of the patient. Although the present invention has been described with reference to preferced embodiments, workers skilled in the art will recognize that changes can be made in form and detail without departing from the spirit and scope of the present invention.

Claims

WHAT IS CLAIMED IS:
1. A prosthetic valve comprising: a body; a first leaflet extending across and coupled to the body, the first leaflet being cut from a first porcine aortic valve and defining a first inner surface; and a second leaflet extending across and coupled to the body opposite the first leaflet, the second leaflet being cut from a second porcine aortic valve and defining a second inner surface.
2. The prosthetic valve of claim 1, wherein the prosthetic mitral valve is configured such that upon closure of the first and second leaflets, the first inner surface and the second inner surface redundantly coapt.
3. The prosthetic valve of claim 1, wherein the first leaflet and the second leaflet are each a left cusp.
4. The prosthetic valve of claim 1, wherein the first and second leaflets each define a free edge, and upon closure of the prosthetic valve, the free edges interact and pucker.
5. The prosthetic valve of claim 1, wherein the first and second leaflets are coupled with the body in a manner characterized by a lack of tautness.
6. The prosthetic valve of claim 1, wherein the first and second leaflets each define a cut edge fixed to the body, a free edge not fixed to the body, and the first and second inner surfaces coapt with each other along a catenary spaced from the free edges, and further wherein the catenary represents a line of interaction between the first and second leaflets nearest the cut edge.
7. The prosthetic valve of claim 6, wherein upon closure of the prosthetic valve, the first inner surface and the second inner surface interact to define an enhanced surface area interface between the catenary and the free edges.
8. The prosthetic valve of claim 6, wherein each of the free edges has a length that is longer than a length of the catenary.
9. The prosthetic valve of claim 6, wherein upon opening of the first and second leaflets, the first and second free edges define an opening, the opening having a perimeter greater than twice a length of the catenary.
10. The prosthetic valve of claim 1, wherein the prosthetic mitral valve is characterized by the absence of a third leaflet.
11. The prosthetic valve of claim 1 , wherein the body includes a stent including an annular frame, a first strut extending from the annular frame, and a second strut spaced from the first strut and extending from the annular frame.
12. The prosthetic valve of claim 10, wherein the first strut and the second strut are nonsymmetrically positioned with respect to the annular frame.
13. The prosthetic valve of claim 1 , wherein the prosthetic valve is a prosthetic mitral valve.
14. The prosthetic valve of claim 1, wherein the body includes a tubular body.
15. The prosthetic valve of claim 14, wherein the tubular body is an aortic root.
16. A prosthetic valve comprising: a body; a first leaflet extending across and sutured to the body, the first leaflet having an elongated shape; and a second leaflet extending across and is sutured to the body opposite the first leaflet, the second leaflet having an elongated shape.
17. The prosthetic valve of claim 16, wherein the first leaflet is cut from a first porcine aortic valve, and the second leaflet is cut from a second porcine aortic valve.
18. The prosthetic valve of claim 17, wherein the first and second leaflets are each a left cusp.
19. The prosthetic valve of claim 16, wherein the first leaflet defines a first inner surface and the second leaflet defines a second inner surface, and further wherein upon closure of the prosthetic valve, the first surface redundantly coapts with the second surface.
20. The prosthetic valve of claim 16, wherein the first leaflet and the second leaflet each define a cut edge sutured to the body, a free edge not sutured to the body, and an inner surface, the inner surface adapted to coapt with each other along a catenary, the catenary being spaced from the free edges and representing a line of interaction between the first and second leaflets nearest the cut edge.
21. The prosthetic valve of claim 20, wherein each of the free edges has a length that is longer than a length of the catenary.
22. The prosthetic valve of claim 20, wherein upon opening the prosthetic valve, the free edges define an opening having a perimeter greater than the twice a length of the catenary.
23. The prosthetic valve of claim 20, wherein upon closure of the prosthetic valve, the first and second inner surfaces interact to define an enhanced surface area interface between the catenary and the free edges.
24. The prosthetic valve of claim 16, wherein the first and second leaflets each define a free edge not sutured to the body, and upon closure of the prosthetic valve, the free edges pucker.
25. The prosthetic valve of claim 16, wherein the first and second leaflets are coupled to the body in a manner characterized by a lack of tautness.
26. The prosthetic valve of claim 16, wherein the body includes a stent including an annular frame, a first strut extending from the annular frame, and a second strut spaced from the first strut and extending from the annular frame.
27. The prosthetic valve of claim 26, wherein the first strut and the second strut are nonsymmetrically positioned with respect to the annular frame.
28. The prosthetic valve of claim 16, wherein the prosthetic valve is a prosthetic mitral valve.
29. The prosthetic valve of claim 16, wherein the body includes a tubular body
30. The prosthetic valve of claim 29, wherein the tubular body is an aortic root.
31. A prosthetic valve comprising: a body; a first leaflet extending across and sutured to the body, the first leaflet being cut from a first porcine aortic valve, defining a first inner surface, and having an elongated shape; and a second leaflet extending across and sutured to the body opposite the first leaflet, the second leaflet being cut from a second porcine aortic valve, defining a second inner surface, and having an elongated shape.
32. A method of manufacturing a prosthetic valve, the method comprising: providing a body; cutting a first leaflet defining a first inner surface from a first porcine aortic valve; coupling the first leaflet to the body; cutting a second leaflet defining a second inner surface from a second porcine aortic valve; and coupling the second leaflet to the body opposite the first leaflet.
33. The method of claim 32, wherein the first leaflet and the second leaflet are each a left cusp.
34. The method of claim 32, wherein coupling the first leaflet and the second leaflet to the first and second struts includes positioning the first leaflet and the second leaflet upon the body such that the first and second inner surfaces redundantly coapt upon closure of the prosthetic valve.
35. The method of claim 32, wherein coupling the first leaflet and coupling the second leaflet to the first and second struts includes leaving a first free edge of the first leaflet and a second free edge of the second leaflet unsutured to the body, respectively, wherein the free edges are adapted to pucker upon closure of the prosthetic valve.
36. The method of claim 32, wherein cutting the first and second leaflets includes selecting the first and second leaflets from a plurality of porcine aortic valves previously harvested for potential use in a prosthetic aortic valve.
37. The method of claim 32, wherein cutting the first and second leaflets includes selecting the first and second leaflets from a plurality of leaflets, and each of the plurality of leaflets differs in size from each of the other plurality of leaflets.
38. The method of claim 37, wherein selecting the first and second leaflets includes selecting the first and second leaflets each having a size corresponding to a size of the body.
39. The method of claim 32, wherein the body includes a stent including an annular frame, a first stent extending from the annular frame, and a second strut extending from the amiular frame spaced from the first stent.
40. The method of claim 32, wherein the body is a tubular body.
EP05705043A 2004-01-07 2005-01-05 Bileaflet prosthetic valve and method of manufacture Withdrawn EP1711130A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/752,864 US20050149181A1 (en) 2004-01-07 2004-01-07 Bileaflet prosthetic valve and method of manufacture
PCT/US2005/000235 WO2005067821A1 (en) 2004-01-07 2005-01-05 Bileaflet prosthetic valve and method of manufacture

Publications (1)

Publication Number Publication Date
EP1711130A1 true EP1711130A1 (en) 2006-10-18

Family

ID=34711692

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05705043A Withdrawn EP1711130A1 (en) 2004-01-07 2005-01-05 Bileaflet prosthetic valve and method of manufacture

Country Status (6)

Country Link
US (1) US20050149181A1 (en)
EP (1) EP1711130A1 (en)
JP (1) JP2007517595A (en)
AU (1) AU2005204649B2 (en)
CA (1) CA2552518A1 (en)
WO (1) WO2005067821A1 (en)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6006134A (en) * 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US8579966B2 (en) 1999-11-17 2013-11-12 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
US8016877B2 (en) 1999-11-17 2011-09-13 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US7749245B2 (en) 2000-01-27 2010-07-06 Medtronic, Inc. Cardiac valve procedure methods and devices
WO2002005888A1 (en) 2000-06-30 2002-01-24 Viacor Incorporated Intravascular filter with debris entrapment mechanism
US6602286B1 (en) 2000-10-26 2003-08-05 Ernst Peter Strecker Implantable valve system
US8771302B2 (en) 2001-06-29 2014-07-08 Medtronic, Inc. Method and apparatus for resecting and replacing an aortic valve
US7544206B2 (en) 2001-06-29 2009-06-09 Medtronic, Inc. Method and apparatus for resecting and replacing an aortic valve
US8623077B2 (en) 2001-06-29 2014-01-07 Medtronic, Inc. Apparatus for replacing a cardiac valve
FR2826863B1 (en) 2001-07-04 2003-09-26 Jacques Seguin ASSEMBLY FOR PLACING A PROSTHETIC VALVE IN A BODY CONDUIT
US7097659B2 (en) 2001-09-07 2006-08-29 Medtronic, Inc. Fixation band for affixing a prosthetic heart valve to tissue
US6752828B2 (en) 2002-04-03 2004-06-22 Scimed Life Systems, Inc. Artificial valve
US6945957B2 (en) 2002-12-30 2005-09-20 Scimed Life Systems, Inc. Valve treatment catheter and methods
US9579194B2 (en) 2003-10-06 2017-02-28 Medtronic ATS Medical, Inc. Anchoring structure with concave landing zone
US8128681B2 (en) 2003-12-19 2012-03-06 Boston Scientific Scimed, Inc. Venous valve apparatus, system, and method
US7854761B2 (en) 2003-12-19 2010-12-21 Boston Scientific Scimed, Inc. Methods for venous valve replacement with a catheter
US20050149181A1 (en) * 2004-01-07 2005-07-07 Medtronic, Inc. Bileaflet prosthetic valve and method of manufacture
US7320705B2 (en) * 2004-01-23 2008-01-22 James Quintessenza Bicuspid pulmonary heart valve and method for making same
US7862610B2 (en) * 2004-01-23 2011-01-04 James Quintessenza Bicuspid vascular valve and methods for making and implanting same
ITTO20040135A1 (en) 2004-03-03 2004-06-03 Sorin Biomedica Cardio Spa CARDIAC VALVE PROSTHESIS
CN101052359A (en) 2004-04-23 2007-10-10 3F医疗有限公司 Implantable prosthetic valve
US7566343B2 (en) 2004-09-02 2009-07-28 Boston Scientific Scimed, Inc. Cardiac valve, system, and method
DE102005003632A1 (en) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Catheter for the transvascular implantation of heart valve prostheses
US20060173490A1 (en) 2005-02-01 2006-08-03 Boston Scientific Scimed, Inc. Filter system and method
US7854755B2 (en) 2005-02-01 2010-12-21 Boston Scientific Scimed, Inc. Vascular catheter, system, and method
US7878966B2 (en) 2005-02-04 2011-02-01 Boston Scientific Scimed, Inc. Ventricular assist and support device
US7670368B2 (en) 2005-02-07 2010-03-02 Boston Scientific Scimed, Inc. Venous valve apparatus, system, and method
US7780722B2 (en) 2005-02-07 2010-08-24 Boston Scientific Scimed, Inc. Venous valve apparatus, system, and method
ITTO20050074A1 (en) 2005-02-10 2006-08-11 Sorin Biomedica Cardio Srl CARDIAC VALVE PROSTHESIS
US7867274B2 (en) 2005-02-23 2011-01-11 Boston Scientific Scimed, Inc. Valve apparatus, system and method
US7722666B2 (en) 2005-04-15 2010-05-25 Boston Scientific Scimed, Inc. Valve apparatus, system and method
US7914569B2 (en) * 2005-05-13 2011-03-29 Medtronics Corevalve Llc Heart valve prosthesis and methods of manufacture and use
US8012198B2 (en) 2005-06-10 2011-09-06 Boston Scientific Scimed, Inc. Venous valve, system, and method
EP1898840A1 (en) * 2005-06-27 2008-03-19 The Cleveland Clinic Foundation Apparatus for placement in the annulus of a tricuspid valve
US7569071B2 (en) 2005-09-21 2009-08-04 Boston Scientific Scimed, Inc. Venous valve, system, and method with sinus pocket
US20070078510A1 (en) 2005-09-26 2007-04-05 Ryan Timothy R Prosthetic cardiac and venous valves
US7799038B2 (en) 2006-01-20 2010-09-21 Boston Scientific Scimed, Inc. Translumenal apparatus, system, and method
US8075615B2 (en) 2006-03-28 2011-12-13 Medtronic, Inc. Prosthetic cardiac valve formed from pericardium material and methods of making same
US11304800B2 (en) 2006-09-19 2022-04-19 Medtronic Ventor Technologies Ltd. Sinus-engaging valve fixation member
US8414643B2 (en) 2006-09-19 2013-04-09 Medtronic Ventor Technologies Ltd. Sinus-engaging valve fixation member
US8834564B2 (en) 2006-09-19 2014-09-16 Medtronic, Inc. Sinus-engaging valve fixation member
US20120083880A1 (en) * 2010-09-30 2012-04-05 BioStable Science & Engineering, Inc. Intra-Annular Mounting Frame For Aortic Valve Repair
US8163011B2 (en) 2006-10-06 2012-04-24 BioStable Science & Engineering, Inc. Intra-annular mounting frame for aortic valve repair
EP2083901B1 (en) 2006-10-16 2017-12-27 Medtronic Ventor Technologies Ltd. Transapical delivery system with ventriculo-arterial overflow bypass
JP5593545B2 (en) 2006-12-06 2014-09-24 メドトロニック シーブイ ルクセンブルク エス.アー.エール.エル. System and method for transapical delivery of a self-expanding valve secured to an annulus
US8133270B2 (en) 2007-01-08 2012-03-13 California Institute Of Technology In-situ formation of a valve
US7967853B2 (en) 2007-02-05 2011-06-28 Boston Scientific Scimed, Inc. Percutaneous valve, system and method
WO2008103295A2 (en) 2007-02-16 2008-08-28 Medtronic, Inc. Replacement prosthetic heart valves and methods of implantation
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
FR2915087B1 (en) 2007-04-20 2021-11-26 Corevalve Inc IMPLANT FOR TREATMENT OF A HEART VALVE, IN PARTICULAR OF A MITRAL VALVE, EQUIPMENT INCLUDING THIS IMPLANT AND MATERIAL FOR PLACING THIS IMPLANT.
US8828079B2 (en) 2007-07-26 2014-09-09 Boston Scientific Scimed, Inc. Circulatory valve, system and method
US8747458B2 (en) 2007-08-20 2014-06-10 Medtronic Ventor Technologies Ltd. Stent loading tool and method for use thereof
US10856970B2 (en) 2007-10-10 2020-12-08 Medtronic Ventor Technologies Ltd. Prosthetic heart valve for transfemoral delivery
US9848981B2 (en) 2007-10-12 2017-12-26 Mayo Foundation For Medical Education And Research Expandable valve prosthesis with sealing mechanism
EP3311779A1 (en) * 2007-10-25 2018-04-25 Symetis SA Stents, valved-stents and methods and systems for delivery thereof
US7892276B2 (en) 2007-12-21 2011-02-22 Boston Scientific Scimed, Inc. Valve with delayed leaflet deployment
US8157852B2 (en) 2008-01-24 2012-04-17 Medtronic, Inc. Delivery systems and methods of implantation for prosthetic heart valves
JP5687070B2 (en) 2008-01-24 2015-03-18 メドトロニック,インコーポレイテッド Stent for prosthetic heart valve
EP2254512B1 (en) 2008-01-24 2016-01-06 Medtronic, Inc. Markers for prosthetic heart valves
US9393115B2 (en) 2008-01-24 2016-07-19 Medtronic, Inc. Delivery systems and methods of implantation for prosthetic heart valves
WO2009094197A1 (en) 2008-01-24 2009-07-30 Medtronic, Inc. Stents for prosthetic heart valves
US9149358B2 (en) 2008-01-24 2015-10-06 Medtronic, Inc. Delivery systems for prosthetic heart valves
WO2011104269A1 (en) 2008-02-26 2011-09-01 Jenavalve Technology Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
WO2009108355A1 (en) 2008-02-28 2009-09-03 Medtronic, Inc. Prosthetic heart valve systems
US8313525B2 (en) 2008-03-18 2012-11-20 Medtronic Ventor Technologies, Ltd. Valve suturing and implantation procedures
US8430927B2 (en) 2008-04-08 2013-04-30 Medtronic, Inc. Multiple orifice implantable heart valve and methods of implantation
US8696743B2 (en) 2008-04-23 2014-04-15 Medtronic, Inc. Tissue attachment devices and methods for prosthetic heart valves
US8312825B2 (en) 2008-04-23 2012-11-20 Medtronic, Inc. Methods and apparatuses for assembly of a pericardial prosthetic heart valve
US8323336B2 (en) 2008-04-23 2012-12-04 Medtronic, Inc. Prosthetic heart valve devices and methods of valve replacement
US9173737B2 (en) 2008-04-23 2015-11-03 Medtronic, Inc. Stented heart valve devices
EP2119417B2 (en) 2008-05-16 2020-04-29 Sorin Group Italia S.r.l. Atraumatic prosthetic heart valve prosthesis
EP2358307B1 (en) 2008-09-15 2021-12-15 Medtronic Ventor Technologies Ltd. Prosthetic heart valve having identifiers for aiding in radiographic positioning
US8721714B2 (en) 2008-09-17 2014-05-13 Medtronic Corevalve Llc Delivery system for deployment of medical devices
US8137398B2 (en) 2008-10-13 2012-03-20 Medtronic Ventor Technologies Ltd Prosthetic valve having tapered tip when compressed for delivery
EP2201911B1 (en) 2008-12-23 2015-09-30 Sorin Group Italia S.r.l. Expandable prosthetic valve having anchoring appendages
US8512397B2 (en) 2009-04-27 2013-08-20 Sorin Group Italia S.R.L. Prosthetic vascular conduit
US8808369B2 (en) 2009-10-05 2014-08-19 Mayo Foundation For Medical Education And Research Minimally invasive aortic valve replacement
KR101074093B1 (en) 2009-10-21 2011-10-17 주식회사 사이언씨티 Artificial Valve Leaflet and Apparatus for Preparing the Same
KR101132376B1 (en) 2009-10-21 2012-04-03 주식회사 사이언씨티 Artificial Valve Leaflet and Apparatus for Preparing the Same
US9226826B2 (en) 2010-02-24 2016-01-05 Medtronic, Inc. Transcatheter valve structure and methods for valve delivery
US8652204B2 (en) 2010-04-01 2014-02-18 Medtronic, Inc. Transcatheter valve with torsion spring fixation and related systems and methods
KR101066569B1 (en) 2010-04-06 2011-09-21 주식회사 리브라하트 Polymer valve and pulsatile conduit-type vad using the same
CN102883684B (en) 2010-05-10 2015-04-08 爱德华兹生命科学公司 Prosthetic heart valve
IT1400327B1 (en) 2010-05-21 2013-05-24 Sorin Biomedica Cardio Srl SUPPORT DEVICE FOR VALVULAR PROSTHESIS AND CORRESPONDING CORRESPONDENT.
JP2013526388A (en) 2010-05-25 2013-06-24 イエナバルブ テクノロジー インク Artificial heart valve, and transcatheter delivery prosthesis comprising an artificial heart valve and a stent
US9918833B2 (en) 2010-09-01 2018-03-20 Medtronic Vascular Galway Prosthetic valve support structure
US8845720B2 (en) 2010-09-27 2014-09-30 Edwards Lifesciences Corporation Prosthetic heart valve frame with flexible commissures
ES2583629T3 (en) * 2010-09-30 2016-09-21 Biostable Science&Engineering Inc. Aortic valve devices
US9161835B2 (en) 2010-09-30 2015-10-20 BioStable Science & Engineering, Inc. Non-axisymmetric aortic valve devices
EP2486893B1 (en) 2011-02-14 2017-07-05 Sorin Group Italia S.r.l. Sutureless anchoring device for cardiac valve prostheses
EP2486894B1 (en) 2011-02-14 2021-06-09 Sorin Group Italia S.r.l. Sutureless anchoring device for cardiac valve prostheses
GB2488530A (en) * 2011-02-18 2012-09-05 David J Wheatley Heart valve
US8603162B2 (en) 2011-07-06 2013-12-10 Waseda University Stentless artificial mitral valve
US9668859B2 (en) 2011-08-05 2017-06-06 California Institute Of Technology Percutaneous heart valve delivery systems
EP2609893B1 (en) 2011-12-29 2014-09-03 Sorin Group Italia S.r.l. A kit for implanting prosthetic vascular conduits
US10966820B2 (en) * 2012-12-19 2021-04-06 W. L. Gore & Associates, Inc. Geometric control of bending character in prosthetic heart valve leaflets
WO2014144247A1 (en) 2013-03-15 2014-09-18 Arash Kheradvar Handle mechanism and functionality for repositioning and retrieval of transcatheter heart valves
EP2991586A1 (en) 2013-05-03 2016-03-09 Medtronic Inc. Valve delivery tool
CN105491978A (en) 2013-08-30 2016-04-13 耶拿阀门科技股份有限公司 Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
KR101525921B1 (en) * 2014-02-17 2015-06-04 (주) 태웅메디칼 Heart valve bioprosthesis and method of manufacturing
CN107072783B (en) * 2014-05-09 2021-03-19 福达斯公司 Replacement heart valve and methods of use and manufacture thereof
US20160095701A1 (en) * 2014-10-07 2016-04-07 St. Jude Medical, Cardiology Division, Inc. Bi-Leaflet Mitral Valve Design
US9579195B2 (en) * 2015-01-13 2017-02-28 Horizon Scientific Corp. Mitral bileaflet valve
US10709555B2 (en) 2015-05-01 2020-07-14 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
EP3454795B1 (en) 2016-05-13 2023-01-11 JenaValve Technology, Inc. Heart valve prosthesis delivery system for delivery of heart valve prosthesis with introducer sheath and loading system
US10231833B2 (en) 2016-10-28 2019-03-19 Foldax, Inc. Prosthetic heart valves with elastic support structures and related methods
CN110392557A (en) 2017-01-27 2019-10-29 耶拿阀门科技股份有限公司 Heart valve simulation
AU2018383609A1 (en) 2017-12-11 2020-06-18 California Institute Of Technology Systems, devices, and methods relating to the manufacture of intravascularly implantable prosthetic valves
CN108814771B (en) * 2018-03-05 2020-02-21 何铭权 Two-leaf biological valve
AU2018424859B2 (en) 2018-05-23 2024-04-04 Corcym S.R.L. A cardiac valve prosthesis
KR102303291B1 (en) * 2019-04-02 2021-09-16 (주) 타우피엔유메디칼 Artificial valved conduit and method for manufacturing artificial valved conduit
WO2021158509A1 (en) 2020-02-06 2021-08-12 Laplace Interventional Inc. Transcatheter heart valve prosthesis assembled inside heart chambers or blood vessels
CN111904661B (en) * 2020-06-04 2022-12-02 金仕生物科技(常熟)有限公司 Bileaflet valve prosthesis
CN111991119B (en) * 2020-09-14 2022-10-21 金仕生物科技(常熟)有限公司 Bileaflet valve prosthesis with valve ears
US11510777B1 (en) 2022-02-10 2022-11-29 Laplace Interventional Inc. Prosthetic heart valves
US11712336B1 (en) 2022-07-20 2023-08-01 Laplace Interventional Inc. Prosthetic heart valves

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3118468A (en) * 1961-04-20 1964-01-21 Gen Electric Resilient material check valve
US3739402A (en) * 1970-10-15 1973-06-19 Cutter Lab Bicuspid fascia lata valve
US4491986A (en) * 1976-05-12 1985-01-08 Shlomo Gabbay Heart valve
CH624631A5 (en) * 1977-11-29 1981-08-14 Alusuisse
US4340977A (en) * 1980-09-19 1982-07-27 Brownlee Richard T Catenary mitral valve replacement
US4388735A (en) * 1980-11-03 1983-06-21 Shiley Inc. Low profile prosthetic xenograft heart valve
EP0084395B1 (en) * 1982-01-20 1986-08-13 Martin Morris Black Artificial heart valves
IT1156682B (en) * 1982-10-14 1987-02-04 Pro Bio Spe Produz Biolog Spec LOW PROFILE BICUSPID ORGANIC VALVE
US4892541A (en) * 1982-11-29 1990-01-09 Tascon Medical Technology Corporation Heart valve prosthesis
GB8300636D0 (en) * 1983-01-11 1983-02-09 Black M M Heart valve replacements
CA1232407A (en) * 1983-06-23 1988-02-09 David K. Walker Bubble heart valve
IT1180531B (en) * 1984-09-21 1987-09-23 Ge Sv In Srl BICUSPID HEART VALVE PROSTHESIS
US5824060A (en) * 1993-09-29 1998-10-20 Medtronic, Inc. Natural tissue heart valve fixation
US5476510A (en) * 1994-04-21 1995-12-19 Medtronic, Inc. Holder for heart valve
DE69523251T2 (en) * 1994-04-22 2002-07-25 Medtronic Inc SUPPORTED HEART VALVE PROSTHESIS
US5554184A (en) * 1994-07-27 1996-09-10 Machiraju; Venkat R. Heart valve
US5861028A (en) * 1996-09-09 1999-01-19 Shelhigh Inc Natural tissue heart valve and stent prosthesis and method for making the same
DE19625202A1 (en) * 1996-06-24 1998-01-02 Adiam Medizintechnik Gmbh & Co Prosthetic mitral heart valve
US5961549A (en) * 1997-04-03 1999-10-05 Baxter International Inc. Multi-leaflet bioprosthetic heart valve
US6254636B1 (en) * 1998-06-26 2001-07-03 St. Jude Medical, Inc. Single suture biological tissue aortic stentless valve
EP1143882B1 (en) * 1999-01-26 2007-12-05 Edwards Lifesciences Corporation Flexible heart valve
US6364905B1 (en) * 1999-01-27 2002-04-02 Sulzer Carbomedics Inc. Tri-composite, full root, stentless valve
GB0125925D0 (en) * 2001-10-29 2001-12-19 Univ Glasgow Mitral valve prosthesis
US20050149181A1 (en) * 2004-01-07 2005-07-07 Medtronic, Inc. Bileaflet prosthetic valve and method of manufacture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005067821A1 *

Also Published As

Publication number Publication date
WO2005067821A1 (en) 2005-07-28
JP2007517595A (en) 2007-07-05
CA2552518A1 (en) 2005-07-28
US20050149181A1 (en) 2005-07-07
AU2005204649B2 (en) 2011-03-10
AU2005204649A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
AU2005204649B2 (en) Bileaflet prosthetic valve and method of manufacture
US10085836B2 (en) Prosthetic mitral valve
AU772890B2 (en) Aortic annuloplasty ring
US9339381B2 (en) Four-leaflet stented mitral heart valve
US5156621A (en) Stentless bioprosthetic cardiac valve
US6454798B1 (en) Polymer heart valve with helical coaption surface
US6350282B1 (en) Stented bioprosthetic heart valve
US4340977A (en) Catenary mitral valve replacement
AU727250B2 (en) Sewing ring having increased annular coaptation
US8062359B2 (en) Highly flexible heart valve connecting band
CA2671514A1 (en) Prosthetic heart valve structures and related methods
WO2023219979A1 (en) Modular bioprosthetic valves and methods for designing and making them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060807

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MEDTRONIC, INC.

17Q First examination report despatched

Effective date: 20100504

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120801